Abstract 565P
Background
The incidence of early-onset colon cancer (early-onset CC, age <50 years (yrs)) is rising with limited data on its clinical and molecular characteristics. We analyzed a real-world cohort of the AIO ColoPredict Plus (CPP) Registry.
Methods
CPP collects data and tissue from patients (pts) with CC UICC stage I-III. Clinical and molecular characteristics were assessed comparing pts <50yrs with pts 50+ using student’s Test and Fishers exact test. Disease-free survival (DFS) rate at 3 yrs was reported. Comorbidity was assessed by Charlson comorbidity index (CCI). Median follow-up was 28.1 months.
Results
Out of 9215 pts 479 (5%) had early-onset CC (median age 44 yrs (22-49) vs. 72 yrs (50-100) in late-onset CC). There were no significant differences regarding sex or BMI. Younger pts had less comorbidities (CCI 0: 91%) than older pts. (CCI 0: 60%, p <0.001). Interestingly, younger patients had larger tumors (p=0.045), more often lymph node metastases (p=0.002) and thus higher UICC stages (p<0,001). Tumor localization was predominantly left-sided in early- (53%) and right-sided in late-onset CC (61%, p<0,001). Younger pts more often received adjuvant chemotherapy (p<0,001) and more frequently oxaliplatin combinations (p<0,001). Mutational analysis was available in 5045 pts, 5% (264 pts) with early-onset CC. No significant difference in K- or N-RAS mutations or MSI were detected. The KRAS subtype p.G12C and BRAF mutations were significantly less prevalent in early-onset compared to late-onset CC (p=0,03 and p<0,01). Younger pts had a better 3 yrs DFS rate.
Conclusions
Pts with early-onset CC in our unique real-world cohort are more often UICC stage III with left primary tumors and better DFS. They also display distinct molecular features which should be considered when making treatment decisions.
Clinical trial identification
DRKS00004305.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Roche, BioNtech.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10